We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+0.86%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.51B
AUM Growth
+$121M
Cap. Flow
+$179M
Cap. Flow %
11.83%
Top 10 Hldgs %
46.72%
Holding
103
New
28
Increased
19
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$70.7M
2
UNH icon
UnitedHealth
UNH
+$33M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$29.5M
4
ELV icon
Elevance Health
ELV
+$28.2M
5
JBIO
Jade Biosciences
JBIO
+$27.1M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$22.4M
2
HOLX
Hologic
HOLX
+$18.7M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$17.7M
4
MRUS
Merus
MRUS
+$16.3M
5
INSM icon
Insmed
INSM
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.75%
2 Consumer Staples 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VCYT icon
26
Veracyte
VCYT
$3.7B
$19.3M 1.28%
+715,439
New +$20.7M
IART icon
27
Integra LifeSciences
IART
$1.29B
$17M 1.13%
1,387,818
+315,614
+29% +$4.58M
AXGN icon
28
Axogen
AXGN
$2.27B
$15.8M 1.05%
1,459,395
+13,278
+0.9% +$174K
MIRM icon
29
Mirum Pharmaceuticals
MIRM
$6.46B
$15.2M 1.01%
+298,696
New +$13.3M
ASND icon
30
Ascendis Pharma A/S
ASND
$16B
$14.7M 0.97%
85,000
+28,700
+51% +$4.67M
INSP icon
31
Inspire Medical Systems
INSP
$1.45B
$14.1M 0.94%
109,000
+70,000
+179% +$10.2M
TWST icon
32
Twist Bioscience
TWST
$5.7B
$13M 0.86%
+354,401
New +$12.2M
PHVS icon
33
Pharvaris
PHVS
$2.28B
$12.9M 0.85%
732,968
-81,684
-10% -$1.32M
IKT icon
34
Inhibikase Therapeutics
IKT
$342M
$12.3M 0.82%
6,325,000
– –
RIGL icon
35
Rigel Pharmaceuticals
RIGL
$681M
$12.3M 0.82%
658,145
-472,534
-42% -$8.96M
FOCL
36
EDAP TMS S.A.
FOCL
$229M
$12.1M 0.8%
7,309,254
– –
THTX
37
DELISTED
Theratechnologies
THTX
$11.3M 0.75%
4,801,376
– –
SNDX icon
38
Syndax Pharmaceuticals
SNDX
$1.69B
$10.2M 0.68%
1,092,110
+275,500
+34% +$3.03M
CCCC icon
39
C4 Therapeutics
CCCC
$385M
$9.98M 0.66%
6,978,942
– –
ENOV icon
40
Enovis
ENOV
$1.68B
$9.88M 0.65%
+315,000
New +$10.4M
NUVL
41
DELISTED
Nuvalent
NUVL
$9.54M 0.63%
125,000
-89,357
-42% -$6.54M
ESTA icon
42
Establishment Labs
ESTA
$2.72B
$9.05M 0.6%
+211,900
New +$7.39M
JSPR icon
43
Jasper Therapeutics
JSPR
$21M
$8.29M 0.55%
1,494,420
– –
ACLX
44
DELISTED
Arcellx
ACLX
$8.1M 0.54%
123,031
-30,000
-20% -$1.87M
JBIO
45
Jade Biosciences
JBIO
$1.2B
$7.96M 0.53%
+796,744
New +$27.1M
INSM icon
46
Insmed
INSM
$21.4B
$7.32M 0.49%
72,772
-201,500
-73% -$15.4M
ANAB icon
47
AnaptysBio
ANAB
$1.58B
$7.13M 0.47%
321,040
+218,988
+215% +$4.58M
KNSA icon
48
Kiniksa Pharmaceuticals
KNSA
$5.8B
$7.05M 0.47%
254,689
-214,811
-46% -$5.47M
SION
49
Sionna Therapeutics
SION
$2.13B
$6.52M 0.43%
376,000
+136,000
+57% +$1.78M
CBIO
50
Crescent Biopharma
CBIO
$537M
$6.46M 0.43%
+400,000
New +$8.46M
1
2
3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return

Soleus Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Soleus Capital Management held 103 positions worth $1.51B, up 8.7% from $1.39B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Soleus Capital Management deployed $179M of net new capital in Q2 2025, opening 28 new positions and adding to 19 existing holdings. Its largest new stake was UnitedHealth: 86,250 shares worth $26.9M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was TG Therapeutics, an estimated $22.4M trimmed.

  • Soleus Capital Management's largest Q2 2025 buy was UnitedHealth: 86,250 shares worth $26.9M.
  • Soleus Capital Management added most to Krystal Biotech in Q2 2025, an estimated $70.7M increase.
  • Soleus Capital Management's biggest Q2 2025 reduction was TG Therapeutics, cutting an estimated $22.4M.
  • Soleus Capital Management fully exited Hologic in Q2 2025, selling an estimated $18.7M.
  • Soleus Capital Management's ten largest holdings make up 47% of its $1.51B portfolio in Q2 2025.
  • Soleus Capital Management opened 28 new positions and closed 8 in Q2 2025.
  • Soleus Capital Management's portfolio value rose 8.7% quarter-over-quarter to $1.51B.

Based on Soleus Capital Management's 13F filing for Q2 2025, filed 15 Aug 2025.